Ipsen acquires botulinum therapeutic developer
This article was originally published in Scrip
Executive Summary
Ipsen of France has acquired Syntaxin, a privately-held UK biotech developing botulinum toxin therapeutics, for €28m upfront and potential contingent payments to its shareholders of more than €130m dependent on development and commercial milestones. Ipsen already holds around 10% of Syntaxin.